Sentence examples for discontinuation of active from inspiring English sources

Also in the DPS, which was the first individually randomized controlled lifestyle intervention trial, the risk of T2DM was substantially lowered even after discontinuation of active intervention and some improvement was seen in the main CVD risk factors [5], [14], [15].

In this study, two patients developed carpal tunnel syndrome that resolved 5 days after discontinuation of active treatment.

A follow-up of the Finnish Diabetes Prevention Study showed a 43% reduction in diabetes risk over a median of 7 years after discontinuation of active counseling (62).

The team concluded that continuing therapy would be futile, and that discontinuation of active treatment should be presented to the parents as the best option.

Many of the AEs leading to the discontinuation of active treatment in this study have been described previously with native GLP-2 treatment.

The two patients who died did so 22 and 31 days after the study in multiple organ dysfunction syndrome after discontinuation of active life support.

Because the half-life of agomelatine is 2 hours and the drug has no active metabolites, any discontinuation symptoms would be expected during the first week after discontinuation of the active drug.

While most adverse reactions (13 AR (54.2%)) did not lead to any action regarding the study treatment, 3 (12.5%) adverse reactions led to dose change, 6 (25%) adverse reactions to permanent discontinuation of the active treatment and 2 (8.3%) adverse reactions to another treatment.

The RDT design was therefore not optimal, since it required discontinuation of an active agent in the setting of stable disease and/or an evolving clinical response.

We report a case of a 21-year-old HIV-positive African American male with lupus-like glomerulonephritis who progressed to end-stage renal disease upon discontinuation of highly active antiretroviral therapy.

Stable disease is recognised as a significant endpoint in the evaluation of clinical benefit associated with many targeted agents, and a focus on only conventional complete or partial responses assessed in the conventional manner using RECIST[ 41 ] may underestimate efficacy and risk discontinuation of the development of active new agents[ 42 ].